Aktienanalyse zu Neogenomics Inc (NEO)NEONeogenomics Inc

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others. It operates in the Healthcare sector (SERVICES-TESTING LABORATORIES industry).

Currently, Neogenomics Inc is a hold. The stock is priced at $16.65, which is near the lower end of analyst price targets ranging from $16 to $28. The stock has a low RSI of 42.145, indicating it is nearing oversold territory, but the forward P/E ratio of 222.22 suggests it is overvalued based on future earnings expectations. The recent partnership with Indica Labs for AI-driven diagnostics could enhance growth, but the company still faces risks with a high forward P/E and recent negative performance trends.

9 analysts cover NEO: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 14.00.